tetano
Editor, Senior Moderator
Clin Case Rep
. 2022 Jan 13;10(1):e05233.
doi: 10.1002/ccr3.5233. eCollection 2022 Jan.
Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: A case series
Sooraj Vijayan[SUP] 1 2 [/SUP], Kyungmin Hwangbo[SUP] 3 [/SUP], Nick Barkham[SUP] 1 [/SUP]
Affiliations
Abstract
The COVID-19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT-P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment benefitting patients both during the pandemic and beyond.
Keywords: COVID‐19; CT‐P13; CT‐P13 SC; ankylosing spondylitis; case report; case series; infliximab; infliximab SC; infliximab subcutaneous; real‐world evidence.
. 2022 Jan 13;10(1):e05233.
doi: 10.1002/ccr3.5233. eCollection 2022 Jan.
Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: A case series
Sooraj Vijayan[SUP] 1 2 [/SUP], Kyungmin Hwangbo[SUP] 3 [/SUP], Nick Barkham[SUP] 1 [/SUP]
Affiliations
- PMID: 35059197
- PMCID: PMC8757239
- DOI: 10.1002/ccr3.5233
Abstract
The COVID-19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT-P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment benefitting patients both during the pandemic and beyond.
Keywords: COVID‐19; CT‐P13; CT‐P13 SC; ankylosing spondylitis; case report; case series; infliximab; infliximab SC; infliximab subcutaneous; real‐world evidence.